X

Drug Profile

Research Programme: RNA splicing modulators - Skyhawk Therapeutics/Sanofi

Latest Information Update: 11 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Skyhawk Therapeutics
Developer Sanofi; Skyhawk Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action RNA splicing modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Cancer; Immunological disorders

Most Recent Events

06 Jul 2022 Early research in Cancer in USA (unspecified route) before July 2022
06 Jul 2022 Early research in Immunological disorders in USA before July 2022 (unspecified route)
05 Jul 2022 Skyhawk Therapeutics enters into a collaboration agreement with Sanofi for oncology and immunology targets

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com